ClinicalTrials.gg

Program

obexelimab

Also written as “Obexelimab” and “XmAb5871”.

Its studies are mostly in Lupus Erythematosus, Systemic · Immunoglobulin G4-Related Disease · Multiple Sclerosis · Anemia, Hemolytic, Autoimmune, led by 2 companies.

Furthest: phase 3, since Dec 14, 20227 company-led studies, 4 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zenas BioPharma (USA)44 open or runningphase 3since Dec 14, 2022Dec 14, 2022none ahead
Xencor30 open or runningphase 2since Jan 8, 2016Jan 8, 2016none ahead
  • Named in bristol myers squibb’s own pipeline as obexelimab, phase 4, as of Oct 29, 2026 (source).

Also a collaborator on its studies: Bristol-Myers Squibb, ppd-development-lp, icon-plc and parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 8, 2016First study: phase 2 study in Lupus Erythematosus, SystemicNew to XencorXencor · NCT02725515 · 105 enrolled · United States
  2. Mar 4, 2016Phase 2 study in Immunoglobulin G4-Related DiseaseXencor · NCT02725476 · 20 enrolled · United States
  3. Aug 2, 2016Phase 1 study in Healthy VolunteersXencor · NCT02867098 · 50 enrolled · United States
  4. Dec 14, 2022Zenas BioPharma (USA)'s first study: phase 3 study in Immunoglobulin G4-Related DiseaseNew to Zenas BioPharma (USA)Zenas BioPharma (USA) · NCT05662241 · 194 enrolled · United States, Argentina, Canada and more
  5. Mar 13, 2023Phase 3 study in Warm Autoimmune Hemolytic AnemiaZenas BioPharma (USA) · NCT05786573 · 134 enrolled · Italy, Poland, Spain and more
  6. Aug 14, 20242 phase 2 studiesZenas BioPharma (USA) · NCT06559163, NCT06564311

TargetBeta

“A humanized immunoglobulin G1 (IgG1) noncytolytic monoclonal antibody directed against the B-cell-specific cell surface antigen CD-19, Fc-engineered for increased affinity to Fc gamma receptor IIB (FcgRIIB; CD32B), with potential immunomodulatory activity. Upon administration, obexelimab simultan…”NCIt, read by Claude

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06564311Multiple Sclerosis · United States, Austria, Belgium and more2Active, not recruitingZenas BioPharma (USA)Aug 28, 202593
NCT06559163Lupus Erythematosus, Systemic · United States, Belgium, Bulgaria and more2Active, not recruitingZenas BioPharma (USA)Sep 2026190
NCT05786573Warm Autoimmune Hemolytic Anemia · Italy, Poland, Spain and more3Active, not recruitingZenas BioPharma (USA)Jun 30, 2026134
NCT05662241Immunoglobulin G4-Related Disease · United States, Argentina, Canada and more3Active, not recruitingZenas BioPharma (USA)Nov 13, 2025194
NCT02867098Healthy Volunteers · United States1CompletedXencorOct 21, 201650
NCT02725476Immunoglobulin G4-Related Disease · United States2CompletedXencorDec 201720
NCT02725515Lupus Erythematosus, Systemic · United States2CompletedXencorJul 17, 2018105

How it is read

Names in the registry

  • “Obexelimab”, 5 entries
  • “XmAb5871”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.